THANK YOU FOR SUBSCRIBING
Pharma Tech Outlook | Wednesday, October 28, 2020
Steven Roese joins CDMO Frontida as the new vice president of quality.
FREMONT, CA: Frontida BioPharm, minority-owned contract development and manufacturing organization (CDMO), appoint Steven Roese as Vice President of Quality. Mr. Roese joins Frontida with more than 25 years of experience in quality operations and pharmaceutical sector management. Steven’s expertise in multi-site quality firms achievements is an invaluable asset to Frontida’s operational contributions. His demonstrated history of commitment to enhancing procedural effectiveness and achieving product quality enhancements will undoubtedly help Frontida surpass current and new milestones.
Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.
Mr. Roese’s professional engagement within the pharmaceutical sector features proven excellence in managing GMP operations, compliance, quality systems, GCP/GLP oversights, and product manufacturing. Besides, he has overseen the release of commercial drug products and the development of clinical trial programs. Mr. Roese will be responsible for Frontida’s system audit standards, performance metrics, quality assurance, and quality control operations. The Frontida team is pleased to have Steve Roese as its new vice president of quality. His quality background and global experience will offer the required quality leadership during this vital growth phase while maintaining a continuous improvement mindset.
Frontida BioPharm is a U.S. based, minority-owned CDMO offering drug delivery technologies, product development, and manufacturing services for pharmaceutical and consumer health companies. It helps pharmaceutical firms develop, scale-up, and commercial manufacturing of fast and controlled-release oral solid dose, powder, and liquid products, making sure robust product performance and supply of clinical trial materials and commercial products.
From its extensive manufacturing facilities located in Philadelphia, PA, and Aurora, IL, Frontida provides a comprehensive suite of solutions for developing and commercializing prescription, highly potent active compounds, OTC, Phase I through Phase III clinical trial materials, and DEA schedule II – V products.
Additionally, Frontida is armed with multiple commercial packaging lines, validated product serialization, and packaging services for commercial products and clinical trial material supplies. The CDMO has an annual ability to manufacture up to 3 billion tablets and capsules.
More in News